CN1072499C - 一种治疗人体体表慢性溃疡的外用药 - Google Patents
一种治疗人体体表慢性溃疡的外用药 Download PDFInfo
- Publication number
- CN1072499C CN1072499C CN98112800A CN98112800A CN1072499C CN 1072499 C CN1072499 C CN 1072499C CN 98112800 A CN98112800 A CN 98112800A CN 98112800 A CN98112800 A CN 98112800A CN 1072499 C CN1072499 C CN 1072499C
- Authority
- CN
- China
- Prior art keywords
- external
- ulcer
- medicine
- red phosphorus
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 23
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 22
- 230000001684 chronic effect Effects 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title claims description 16
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 14
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 12
- 229940056582 human hair preparation Drugs 0.000 claims abstract description 11
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 10
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 18
- 244000293323 Cosmos caudatus Species 0.000 claims description 9
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 9
- 229960003405 ciprofloxacin Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 2
- 230000036407 pain Effects 0.000 abstract description 10
- 208000027418 Wounds and injury Diseases 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract description 2
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 abstract 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000009172 bursting Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000006385 ozonation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- JKWMSGQKBLHBQQ-UHFFFAOYSA-N diboron trioxide Chemical compound O=BOB=O JKWMSGQKBLHBQQ-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- -1 phosphorus compound Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种用于治疗人体体表慢性溃疡的外用药，由盐酸环丙沙星0.5份，红磷、三七、冰片、血余炭、珍珠组合而成，是一种止痛、抗菌效果好、祛腐生肌能力强、促进创面愈合迅速的外用药。适用于各种外伤性溃疡、烧伤疤痕性溃疡、放射性溃疡、褥疮、瘘窦等。
Description
本发明涉及一种对人体体表慢性溃疡起治疗愈合作用的外用药。
体表慢性溃疡作为一种常见病，其肉芽组织苍白水肿，基底形成致密纤维板，坚硬，缺乏弹性，影响表层肉芽组织的血液供应，且创面细菌普遍耐药，导致创面反复破溃，经久换药难以愈合，病程长，病人痛苦大，临床医生颇感棘手。研制疗效突出的治疗溃疡的外用药物一直是医学界所注重的课题。目前，临床上所使用的治疗体表溃疡的外用药，如“湿润烧伤膏”、“东大贝复剂”等疗效均欠佳，几乎没有专用的治疗溃疡的有效外用药。
本发明的目的在于提供一种止痛迅速、抗菌消炎和祛腐生肌作用显著的治疗人体体表慢性溃疡的中西结合的外用药——伤溃灵。经多家医院临床试验证明，本发明在治疗体表慢性溃疡、烧伤疤痕性溃疡、放射性溃疡、褥疮、瘘窦等方面均取得显著疗效。采用随机分组、阳性药物对照方案，对“伤溃灵”治疗体表慢性溃疡临床疗效及安全性进行系统观察。对照药选择“湿润烧伤膏”和“贝复济”。共观察293例，其中治疗组147例、对照一组(湿润烧伤膏组)88例，对照二组(贝复济组)58例。结果表明，“伤溃灵”治疗体表慢性溃疡显效率为77.6％，总有效率为98.6％，优于“湿润烧伤膏”(P＜0.01)和“贝复济”。临床观察中未见明显不良反应，对血、尿常规及肝、肾功能等指标亦无不良影响。
本发明由多种中、西药材混合研制而成，灰黑色粉末状，气味芳香，无毒，无副作用，无过敏反应。
本发明的目的是这样实现的。
配方为：(以重量计)
由盐酸环丙沙星0.5份、冰片1份、红磷1份、血余炭1份、三七1份、珍珠1份组合而成。
各成份的药理药性：盐酸环丙沙星：分子式：[G17H18FN3OHCLH2O=385.82]
性状：白色或淡黄色、无臭、味苦。
药理作用：具有广谱抗菌作用，对大肠杆菌、克雷伯氏菌和其它肠杆菌种阴性杆菌具有较强的抗菌活性，对绿脓杆菌、金黄色葡萄球菌以及肺炎双球菌、甲型溶血链球菌、乙型溶血链球菌等的抗菌作用优于诺氟沙星、甲磺酸培氟沙星，但本品对链球菌属的抗菌作用不及青霉素类抗菌素。本品抗菌作用机制为抑制细菌DNA螺旋酶，抗菌作用为杀菌型。本品与其它抗生素无交叉耐药性，对β-内酰胺类、氟基糖甙类、磺胺类耐药菌对本品仍敏感。冰片：来源：一种是人工合成龙脑香Dryobdamops aromatica Gaerth.F.以松节油、艾纳香草酸为原料，用硼酸酐催化合成；另一种是以菊科植物Blumeabalsamifera DC.属大枫艾的叶片为原料，经蒸馏加工提取而成，又名艾片。
主要成分：含挥发油，主成分为左旋龙脑，又含少量桉树脑，左旋樟脑。
药理作用：芳香开窍，散热止痛。作用为：Ⅰ、兴奋中枢神经系统。2、抗菌。体外试验其酊剂对金黄色葡萄球菌、大肠杆菌、猪霍乱菌有抑菌作用，其粉剂和青剂对羊毛样小孢子菌、红色毛癣菌等有全抑作用。
性味：辛、苦、微寒。
功能：清热通窍，消肿止痛。红磷(P)：红棕色粉末，无毒，工业上用作火头原料及磷化合物，也供有机合成用。性辛、凉、味涩。功效：收敛止血，消炎镇痛，祛腐生肌。血余炭：即人发加工锻烧而成的炭，性辛、微温。功效：消瘀、止血、镇痛，主要含优角蛋白，水分、灰分、脂肪、氨、硫。三七：来源：为五加科多年生草本植物三七的干燥根。
主要成分：含三七皂甙甲(C30H53O16)、三七皂甙乙(C23H38O16)和黄酮甙。
药理作用：止血、祛瘀、消肿、止痛。其药理为：1、止血。三七温浸液能缩短家兔凝血时间，并有收缩血管作用。2、消炎。三七水煎液对大鼠实验性关节炎有明显抑制作用。3、增加冠脉流量。三七黄酮甙能明显增加心冠状动脉流量，同时心肌耗氧量减少。又三七水煎似具有糖皮质激素样作用。
性味：甘、微苦，温。
功能：止血化瘀、消肿止血。珍珠：甘、咸、寒。入心、肝经，功效：目赤肿痛，咽喉肿痛，口舌生疮，疮疡久溃不敛、解毒，生肌敛疮。配制方法：
盐酸环丙沙星取粉剂，其余五种原料均研成粉末并过120目筛，按比例称量后，先将血余炭、红磷、冰片、珍珠四种粉末混合均匀，经高温消毒灭菌，再将三七经臭氧消毒，最后加入盐酸环丙沙星粉末混合均匀，即可包装应用。
本发明与现有的治疗各种溃疡的外用药相比较，具有如下优点：
一、止痛效果好：本发明具有行气、活血、清热消瘀的功能，各种疼痛的慢性溃疡患者，清创后，只需将药粉撒入创面，三分钟之内疼痛完全控制。
二、抗菌消炎效果显著，本发明具有高效广谱抗菌作用，小面积溃疡感染患者不需口服或注射抗菌药物，单用本品即可痊愈。
三、祛腐生肌能力突出，表浅分泌物少的创面，一般用药3-4天即可长出新鲜肉芽组织，对创面深、脓性坏死组织较多则能使坏死组织自然液化，无损伤性排除，不需用刀钳剪割，病人无痛苦。
四、具有明显的促进周边上皮生长作用。一般溃疡面在5天左右明显缩小。
五、患者用药后，局部刺激小，末见毒副作用及过敏反应，使用方便，是安全有效的局部外用药。
实施例1：
取盐酸环丙沙星粉剂300克、冰片200克、红磷150克、血余炭300克、三七150克、珍珠200克，将冰片、红磷、血余炭、三七、珍珠五种原料均研成粉末并过120目筛，按比例称量后，先将血余炭、红磷、冰片、珍珠四种粉末混合均匀，经高温消毒灭菌，再将三七经臭氧消毒，最后再加入盐酸环丙沙星粉末混和即可包装应用。
实施例2：
取盐酸环丙沙星250克、冰片300克、红磷200克、血余炭400克、三七200克、珍珠100克，加工工艺与实施例1相同。
Claims (1)
1、一种用于治疗人体体表慢性溃疡的外用药，其特征在于由盐酸环丙沙星、红磷、三七、冰片、血余炭、珍珠组成，各成分的重量份数为：盐酸环丙沙星25-30，冰片20-30，红磷15-20，血余炭30-40，三七15-20，珍珠10-20。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98112800A CN1072499C (zh) | 1998-12-28 | 1998-12-28 | 一种治疗人体体表慢性溃疡的外用药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98112800A CN1072499C (zh) | 1998-12-28 | 1998-12-28 | 一种治疗人体体表慢性溃疡的外用药 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1224617A CN1224617A (zh) | 1999-08-04 |
| CN1072499C true CN1072499C (zh) | 2001-10-10 |
Family
ID=5222598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98112800A Expired - Fee Related CN1072499C (zh) | 1998-12-28 | 1998-12-28 | 一种治疗人体体表慢性溃疡的外用药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1072499C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579420B (zh) * | 2008-05-14 | 2011-07-06 | 陈进业 | 治疗麻风病陈旧性溃眼糜烂及烧烫伤的外用药物 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19962470A1 (de) * | 1999-12-22 | 2001-07-12 | Schulz Hans Herrmann | Verwendung von Chemotherapeutika |
| CN105497138A (zh) * | 2015-10-19 | 2016-04-20 | 华南农业大学 | 一种含有金不换和β-内酰胺类抗菌药的畜用复方药物 |
| CN105641007A (zh) * | 2016-01-18 | 2016-06-08 | 刘景春 | 一种治疗褥疮及术后感染的药物 |
| CN111281948A (zh) * | 2020-04-22 | 2020-06-16 | 辽宁宝一堂科技发展有限公司 | 一种百草抑菌膏的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1042305A (zh) * | 1988-11-02 | 1990-05-23 | 薛景贤 | 一种治疗各种炎症、溃疡药的制造方法 |
| CN1093923A (zh) * | 1993-12-09 | 1994-10-26 | 邓目金 | 创伤、溃疡速愈散 |
| CN1098921A (zh) * | 1993-08-14 | 1995-02-22 | 陈兰君 | 溃疡散 |
| CN1176121A (zh) * | 1997-07-25 | 1998-03-18 | 薛景贤 | 一种治疗溃疡的药物及其制备方法 |
-
1998
- 1998-12-28 CN CN98112800A patent/CN1072499C/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1042305A (zh) * | 1988-11-02 | 1990-05-23 | 薛景贤 | 一种治疗各种炎症、溃疡药的制造方法 |
| CN1098921A (zh) * | 1993-08-14 | 1995-02-22 | 陈兰君 | 溃疡散 |
| CN1093923A (zh) * | 1993-12-09 | 1994-10-26 | 邓目金 | 创伤、溃疡速愈散 |
| CN1176121A (zh) * | 1997-07-25 | 1998-03-18 | 薛景贤 | 一种治疗溃疡的药物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 《贵州医药》18(5)1994 1994.1.1 李思奉，环丙沙星软膏治疗化脓性感染皮肤病的临床验证报告 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579420B (zh) * | 2008-05-14 | 2011-07-06 | 陈进业 | 治疗麻风病陈旧性溃眼糜烂及烧烫伤的外用药物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1224617A (zh) | 1999-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davis et al. | Wound healing. Oral and topical activity of Aloe vera | |
| CN103893458B (zh) | 糖尿病足溃疡外用中药组合物、制备方法及其应用 | |
| CN102058781A (zh) | 用于治疗烧烫伤的中药膜剂 | |
| CN102861151B (zh) | 一种治疗褥疮的中药组合物 | |
| CN1072499C (zh) | 一种治疗人体体表慢性溃疡的外用药 | |
| CN102028875B (zh) | 一种治疗开放性外伤的药物及其制备方法 | |
| Ullah et al. | Medicinal plants: an insight into wound healing: medicinal plants & wound healing | |
| CN100471518C (zh) | 五虎白冰散 | |
| CN1186068C (zh) | 具有消炎生肌止痒止痛作用的外用中成药及其制备方法 | |
| CN1068785C (zh) | 一种用于治疗烫伤、烧伤、皮肤溃疡等疾病的外用中成药 | |
| CN102688368B (zh) | 一种用于治疗外伤止血或顽固性溃疡的中药 | |
| CN1317017C (zh) | 一种治疗皮肤溃疡的外用药 | |
| CN101417121B (zh) | 一种治疗皮肤烧烫冻伤的药物 | |
| CN1127970C (zh) | 一种治疗烧伤的药膏及其制备方法 | |
| CN1778360A (zh) | 一种烧烫伤药 | |
| CN100502905C (zh) | 一种抗菌生肌的中药制剂 | |
| CN110624032A (zh) | 一种治疗烧烫伤的膏剂及其制备方法 | |
| WO2014167405A1 (en) | Treating lower limb ulcers with centella asiatica | |
| CN116531460B (zh) | 一种治疗巨大褥疮的中药散剂及其制备方法 | |
| CN108245577B (zh) | 一种烧伤止痛消肿生肌液膏及其制备方法 | |
| CN104689075B (zh) | 治疗压疮的中西药联合的药物 | |
| CN1294915C (zh) | 一种祛腐生肌拔毒丹 | |
| CN109045219B (zh) | 一种用于治疗母兔乳房炎的红茂草复方外用膏剂 | |
| CN1759879A (zh) | 治疗褥疮的中药药膏及其制备方法 | |
| CN1050753C (zh) | 创口愈合剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Mao Heping Document name: payment instructions |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Mao Heping Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |